Protara Therapeutics CEO Jesse Shefferman disposes of 215,687 common shares for $882,156.83PUBT·Jul 1 at 03:11 PMTARA+5.77%
Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Studybenzinga_article·May 15 at 10:36 AMTARA+5.77%SBIO+3.26%
Oppenheimer Keeps Their Buy Rating on Protara Therapeutics (TARA)Tip Ranks·May 14 at 09:06 AMTARA+5.77%IBBQ+0.90%
Protara Therapeutics (TARA) Projected to Post Quarterly Earnings on ThursdayMarket Beat·May 7 at 03:06 AMTARA+5.77%FBT+0.87%
JonesTrading Remains a Buy on Protara Therapeutics (TARA)Tip Ranks·Apr 6 at 03:38 PMSBIO+3.26%XLV-1.64%
Protara Therapeutics Highlights Positive TARA-002 Phase 2 ResultsTip Ranks·Mar 30 at 08:19 AMIBBQ+0.90%SBIO+3.26%
